• YD Bio secured FDA agreement to provide early regulatory guidance on YDB-LMSCEV-001, an investigational biologic eye drop for moderate-to-severe dry eye disease.
• Written feedback is expected by January 4, 2027, covering manufacturing controls and proposed early animal testing.
• Initial laboratory and mouse studies are complete; a proposed follow-up animal study has been submitted for FDA review.
• The feedback will guide manufacturing improvements and confirmatory animal studies ahead of a pre-IND meeting, a regulatory step before human trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121630PRIMZONEFULLFEED9876177) on November 12, 2026, and is solely responsible for the information contained therein.